An Updated Review on Dysregulated lncRNAs and their Contribution to the Various Molecular Types of Lung Carcinoma


Cite item

Full Text

Abstract

Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates. This reveals a need to recognize novel techniques to treat malignancy and decrease the burden of lung cancer. Long noncoding RNAs (lncRNAs) manage vital cellular and biochemical functions. lncRNAs play crucial roles in transcriptional and translational processes and signaling cascades. Recently, lncRNAs have been reported to be associated with malignancy where their expression is deregulated, leading to abnormal cellular activities and signaling pathways. In various malignancies, including lung cancer, lncRNA deregulation disrupts normal cellular function, promoting tumorigenesis and influencing patient outcomes and treatment responses. Studies have shown that lncRNAs can act as both oncogenes and tumor suppressors, depending on the lung cancer subtype, specifically in Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). This dual role of lncRNAs as critical biomarkers might provide insights into lung cancer development and progression. lncRNAs have been discussed as key biomarkers in lung cancer. A comprehensive understanding of the biological activities of lncRNAs in NSCLC and SCLC may improve prognosis, diagnosis, and therapeutic methods. Researchers are increasingly interested in lncRNAs as potential diagnostic biomarkers and therapeutic targets in cancer treatment. As researchers continue to explore lncRNAs, their pivotal roles in lung cancer become increasingly evident. This review highlights the function of lncRNAs in lung carcinogenesis and discusses their molecular mechanisms of function.

About the authors

Narges Dastmalchi

Biology, University College of Nabi Akram

Email: info@benthamscience.net

Mohammad Alipour

Stem Cell Research Center, Tabriz University of Medical Sciences

Email: info@benthamscience.net

Reza Safaralizadeh

Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz

Email: info@benthamscience.net

Khalil Hajiasgharzadeh

Stem Cell Research Center, Tabriz University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res., 2016, 5(3), 288-300. doi: 10.21037/tlcr.2016.06.07
  2. Denisenko, T.V.; Budkevich, I.N.; Zhivotovsky, B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis., 2018, 9(2), 117. doi: 10.1038/s41419-017-0063-y
  3. Souza, V.G.P.; de Araújo, R.P.; Santesso, M.R.; Seneda, A.L.; Minutentag, I.W.; Felix, T.F.; H Filho, P.T.; Pewarchuk, M.E.; Brockley, L.J.; Marchi, F.A.; Lam, W.L.; Drigo, S.A.; Reis, P.P. Advances in the molecular landscape of lung cancer brain metastasis. Cancers (Basel), 2023, 15(3), 722. doi: 10.3390/cancers15030722
  4. Mezentsev, A.; Durymanov, M.; Makarov, V.A. A comprehensive review of protein biomarkers for invasive lung cancer. Curr. Oncol., 2024, 31(9), 4818-4854. doi: 10.3390/curroncol31090360
  5. Arunkumar, G. LncRNAs: The good, the bad, and the unknown. Biochem. Cell Biol., 2024, 102(1), 9-27. doi: 10.1139/bcb-2023-0155
  6. Hu, Q.; Ma, H.; Chen, H.; Zhang, Z.; Xue, Q. LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside. Cell Death Discov., 2022, 8(1), 359. doi: 10.1038/s41420-022-01157-4
  7. Dastmalchi, N.; Safaralizadeh, R.; Latifi-Navid, S.; Banan Khojasteh, S.M.; M Hussen, B.; Teimourian, S. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer. Expert Rev. Mol. Diagn., 2021, 21(10), 1025-1036. doi: 10.1080/14737159.2021.1962707
  8. Dastmalchi, N.; Safaralizadeh, R.; Banan, K.S.M. The correlation between microRNAs and Helicobacter pylori in gastric cancer. Pathog. Dis., 2019, 77(4), ftz039. doi: 10.1093/femspd/ftz039
  9. Dastmalchi, N.; Safaralizadeh, R.; Nargesi, M.M. LncRNAs: Potential novel prognostic and diagnostic biomarkers in colorectal cancer. Curr. Med. Chem., 2020, 27(30), 5067-5077. doi: 10.2174/0929867326666190227230024
  10. Mohammadrezakhani, H.; Baradaran, B.; Shanehbandi, D.; Asadi, M.; Hashemzadeh, S.; Hajiasgharzadeh, K.; Safaralizadeh, R. Overexpression and clinicopathological correlation of long noncoding RNA TMPO-AS1 in colorectal cancer patients. J. Gastrointest. Cancer, 2020, 51(3), 952-956. doi: 10.1007/s12029-019-00333-7
  11. Ghodrati, R.; Safaralizadeh, R.; Dastmalchi, N.; Hosseinpourfeizi, M.; Asadi, M.; Shirmohammadi, M.; Baradaran, B. Overexpression of lncRNA DLEU1 in gastric cancer tissues compared to adjacent non-tumor tissues. J. Gastrointest. Cancer, 2022, 53(4), 990-994. doi: 10.1007/s12029-021-00733-8
  12. Gencel-Augusto, J.; Wu, W.; Bivona, T.G. long non-coding RNAs as emerging targets in lung cancer. Cancers (Basel), 2023, 15(12), 3135. doi: 10.3390/cancers15123135
  13. Lu, T.; Wang, Y.; Chen, D.; Liu, J.; Jiao, W. Potential clinical application of lncRNAs in non-small cell lung cancer. OncoTargets Ther., 2018, 11, 8045-8052. doi: 10.2147/OTT.S178431
  14. Chen, X.; Zhou, F.; Ren, W.; Guo, J.; Huang, X.; Pu, J.; Niu, X.; Jiang, X. LncRNA-AC02278.4 Is a novel prognostic biomarker that promotes tumor growth and metastasis in lung Adenocarcinoma. Front. Oncol., 2022, 12, 860961. doi: 10.3389/fonc.2022.860961
  15. Chen, C.; Liu, W.R.; Zhang, B.; Zhang, L.M.; Li, C.G.; Liu, C.; Zhang, H.; Huo, Y-S.; Ma, Y-C.; Tian, P-F.; Qi, Q.; Li, J-J.; Tang, Z.; Zhang, Z-F.; Giaccone, G.; Yue, D-S.; Wang, C-L. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. Cancer Lett., 2020, 486, 58-70. doi: 10.1016/j.canlet.2020.05.009
  16. Wang, M.; Fu, Y.; Zhong, C.; Gacche, R.N.; Wu, P. Long non-coding RNA and evolving drug resistance in lung cancer. Heliyon, 2023, 9(12), e22591. doi: 10.1016/j.heliyon.2023.e22591
  17. Liu, D.; Lu, X.; Huang, W.; Zhuang, W. Long non-coding RNAs in non-small cell lung cancer: Implications for EGFR-TKI resistance. Front. Genet., 2023, 14, 1222059. doi: 10.3389/fgene.2023.1222059
  18. Guo, X.; Xia, J.; Deng, K. Long non-coding RNAs: Emerging players in gastric cancer. Tumour Biol., 2014, 35(11), 10591-10600. doi: 10.1007/s13277-014-2548-y
  19. Da, C.; Gong, C.Y.; Nan, W.; Zhou, K.S.; Wu, Z-L.; Zhang, H-H. The role of long non-coding RNA MIAT in cancers. Biomed. Pharmacother., 2020, 129, 110359. doi: 10.1016/j.biopha.2020.110359
  20. Lei, T.; Lv, Z.Y.; Fu, J.F.; Wang, Z.; Fan, Z.; Wang, Y. LncRNA NBAT-1 is down-regulated in lung cancer and influences cell proliferation, apoptosis and cell cycle. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(7), 1958-1962.
  21. Chen, T.; Gao, F.; Yang, T.; Li, H.; Li, Y.; Ren, H.; Chen, M. LncRNA HOTAIRM1 inhibits the proliferation and invasion of lung adenocarcinoma cells via the miR-498/WWOX axis. Cancer Manag. Res., 2020, 12, 4379-4390. doi: 10.2147/CMAR.S244573
  22. Kadian, L.K.; Verma, D.; Lohani, N.; Yadav, R.; Ranga, S.; Gulshan, G.; Pal, S.; Kumari, K.; Chauhan, S.S. Long non-coding RNAs in cancer: Multifaceted roles and potential targets for immunotherapy. Mol. Cell. Biochem., 2024, 9(12), 3229-3254. doi: 10.1007/s11010-024-04933-1
  23. Wang, R.; Xu, Y.; Tong, L.; Zhang, X.; Zhang, S. Recent progress of exosomal lncRNA/circRNA–miRNA–mRNA axis in lung cancer: Implication for clinical application. Front. Mol. Biosci., 2024, 11, 1417306. doi: 10.3389/fmolb.2024.1417306
  24. Park, S.M.; Choi, E.Y.; Bae, D.H.; Sohn, H.A.; Kim, S.Y.; Kim, Y.J. The LncRNA EPEL promotes lung cancer cell proliferation through E2F target activation. Cell. Physiol. Biochem., 2018, 45(3), 1270-1283. doi: 10.1159/000487460
  25. Ma, J.; Cao, K.; Ling, X.; Zhang, P.; Zhu, J. LncRNA HAR1A suppresses the development of non-small cell lung cancer by inactivating the STAT3 pathway. Cancers (Basel), 2022, 14(12), 2845. doi: 10.3390/cancers14122845
  26. Wu, C.; Yang, J.; Li, R.; Lin, X.; Wu, J.; Wu, J. LncRNA WT1-AS/miR-494-3p regulates cell proliferation, apoptosis, migration and invasion via PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer. OncoTargets Ther., 2021, 14, 891-904. doi: 10.2147/OTT.S278233
  27. Liu, M.; Liu, C.; Li, X.; Li, S. RP11-79H23.3 Inhibits the proliferation and metastasis of non-small-cell lung cancer through promoting miR-29c. Biochem. Genet., 2023, 61(2), 506-520. doi: 10.1007/s10528-022-10263-y
  28. Lai, X.N.; Li, J.; Tang, L.B.; Chen, W.T.; Zhang, L.; Xiong, L.X. MiRNAs and LncRNAs: Dual roles in TGF-β signaling-regulated metastasis in lung cancer. Int. J. Mol. Sci., 2020, 21(4), 1193. doi: 10.3390/ijms21041193
  29. Li, X.; Wu, Y.; Jin, Y. Exosomal LncRNAs and CircRNAs in lung cancer: Emerging regulators and potential therapeutic targets. Noncoding RNA Res., 2024, 9(4), 1069-1079. doi: 10.1016/j.ncrna.2024.06.010
  30. Cheng, Z.; Lu, C.; Wang, H.; Wang, N.; Cui, S.; Yu, C.; Wang, C.; Zuo, Q.; Wang, S.; Lv, Y.; Yao, M.; Jiang, L.; Qin, W. Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression. Cancer Lett., 2022, 531, 1-13. doi: 10.1016/j.canlet.2022.01.031
  31. Gao, J.; Pan, T.; Wang, H.; Wang, S.; Chai, J.; Jin, C. LncRNA FAM138B inhibits the progression of non-small cell lung cancer through miR-105-5p. Cell Cycle, 2023, 22(7), 808-817. doi: 10.1080/15384101.2022.2154556
  32. Miliotis, C.; Slack, F.J. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Lett., 2021, 518, 115-126. doi: 10.1016/j.canlet.2021.05.037
  33. Sun, X.; Qiu, X. LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis. Am. J. Transl. Res., 2021, 13(8), 8653-8669.
  34. Pan, H.; Peng, J.; Qiao, X.; Gao, H. Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis. Open Med. (Wars.), 2023, 18(1), 20230666. doi: 10.1515/med-2023-0666
  35. Taghvimi, S.; Abbaszadeh, S.; Banan, F.B.; Fard, E.S.; Jamali, Z.; Najafabadi, M.A.; Savardashtaki, A.; Movahedpour, A. LncRNAs roles in chemoresistance of cancer cells. Curr. Mol. Med., 2022, 22(8), 691-702. doi: 10.2174/1566524021666211027090515
  36. Guo, S.; Zhang, L.; Zhang, Y.; Wu, Z.; He, D.; Li, X.; Wang, Z. Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition. Aging (Albany NY), 2019, 11(18), 7553-7569. doi: 10.18632/aging.102271
  37. Xia, H.; Qu, X-L.; Liu, L-Y.; Qian, D-H.; Jing, H-Y. LncRNA MEG3 promotes the sensitivity of vincristine by inhibiting autophagy in lung cancer chemotherapy. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(4)
  38. Yang, T.; Li, H.; Chen, T.; Ren, H.; Shi, P.; Chen, M. LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis. Mol. Cells, 2019, 42(3), 270-283.
  39. Pan, H.; Yu, T.; Sun, L.; Chai, W.; Liu, X.; Yan, M. LncRNA FENDRR-mediated tumor suppression and tumor-immune microenvironment changes in non-small cell lung cancer. Transl. Cancer Res., 2020, 9(6), 3946-3959. doi: 10.21037/tcr-20-2147
  40. Wang, C.; Tao, X.; Wei, J. Effects of LncRNA MEG3 on immunity and autophagy of non-small cell lung carcinoma through IDO signaling pathway. World J. Surg. Oncol., 2021, 19(1), 244. doi: 10.1186/s12957-021-02346-8
  41. Zhu, Y.; Shen, Y.; Chen, R.; Li, H.; Wu, Y.; Zhang, F.; Huang, W.; Guo, L.; Chen, Q.; Liu, H. KCNQ1OT1 lncRNA affects the proliferation, apoptosis, and chemoresistance of small cell lung cancer cells via the JAK2/STAT3 axis. Ann. Transl. Med., 2021, 9(10), 891-891. doi: 10.21037/atm-21-1761
  42. Yuan, X.; Shen, Q.; Ma, W. Long noncoding RNA hotair promotes the progression and immune escape in laryngeal squamous cell carcinoma through MicroRNA-30a/GRP78/PD-L1 axis. J. Immunol. Res., 2022, 2022, 1-13.
  43. Chen, W.; Hang, Y.; Xu, W.; Wu, J.; Chen, L.; Chen, J.; Mao, Y.; Song, J.; Song, J.; Wang, H. BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small‐cell lung cancer. J. Cell. Biochem., 2019, 120(2), 2540-2546. doi: 10.1002/jcb.27548
  44. Huang, Y.; Xia, L.; Tan, X.; Zhang, J.; Zeng, W.; Tan, B.; Yu, X.; Fang, W.; Yang, Z. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. Cell. Mol. Biol. Lett., 2022, 27(1), 43. doi: 10.1186/s11658-022-00343-7
  45. Xia, Y.; Wang, W.C.; Shen, W.H.; Xu, K.; Hu, Y.Y.; Han, G.H.; Liu, Y-B. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454–3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem. Biol. Interact., 2021, 349, 109652. doi: 10.1016/j.cbi.2021.109652
  46. Shen, Q.; Zhou, H.; Zhang, M.; Wu, R.; Wang, L.; Wang, Y.; Chen, J. Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. J. Clin. Lab. Anal., 2022, 36(6), e24460. doi: 10.1002/jcla.24460
  47. Yan, Z.; Yang, Q.; Xue, M.; Wang, S.; Hong, W.; Gao, X. YY1-induced lncRNA ZFPM2-AS1 facilitates cell proliferation and invasion in small cell lung cancer via upregulating of TRAF4. Cancer Cell Int., 2020, 20(1), 108. doi: 10.1186/s12935-020-1157-7
  48. Dao, R.; Wudu, M.; Hui, L.; Jiang, J.; Xu, Y.; Ren, H.; Qiu, X. Knockdown of lncRNA MIR503HG suppresses proliferation and promotes apoptosis of non-small cell lung cancer cells by regulating miR-489-3p and miR-625-5p. Pathol. Res. Pract., 2020, 216(3), 152823. doi: 10.1016/j.prp.2020.152823
  49. Zhang, Y.; Li, Y.; Han, L.; Zhang, P.; Sun, S. SBF2‐AS1: An oncogenic lncRNA in small‐cell lung cancer. J. Cell. Biochem., 2019, 120(9), 15422-15428. doi: 10.1002/jcb.28809
  50. Luo, H.; Zhang, Y.; Qin, G.; Jiang, B.; Miao, L. LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer. BMC Cancer, 2021, 21(1), 820. doi: 10.1186/s12885-021-08365-8
  51. Wang, D.; Wu, W.; Huang, W.; Wang, J.; Luo, L.; Tang, D. LncRNA LUADT1 sponges miR-15a-3p to upregulate Twist1 in small cell lung cancer. BMC Pulm. Med., 2019, 19(1), 246. doi: 10.1186/s12890-019-0991-7
  52. Pan, J.; Fang, S.; Tian, H.; Zhou, C.; Zhao, X.; Tian, H.; He, J.; Shen, W.; Meng, X.; Jin, X.; Gong, Z. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling. Mol. Cancer, 2020, 19(1), 9. doi: 10.1186/s12943-020-1133-9
  53. Su, H.; Fan, G.; Huang, J.; Qiu, X. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis., 2022, 13(4), 307. doi: 10.1038/s41419-022-04723-x
  54. Li, B.; Zhu, L.; Li, L.; Ma, R. lncRNA OXCT1-AS1 promotes metastasis in non-small-cell lung cancer by stabilizing LEF1, in vitro and in vivo. Biomed Res. Int., 2021, 2021, 1-15.
  55. Lu, G.; Zhang, Y. Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p. PLoS One., 2020, 15(2), e0229118. doi: 10.1371/journal.pone.0229118
  56. Güçlü, E.; Eroğlu Güneş, C.; Kurar, E.; Vural, H. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. Med. Oncol., 2021, 38(9), 113. doi: 10.1007/s12032-021-01562-2
  57. Zeng, F.; Wang, Q.; Wang, S.; Liang, S.; Huang, W.; Guo, Y.; Peng, J.; Li, M.; Zhu, W.; Guo, L. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene, 2020, 39(2), 293-307. doi: 10.1038/s41388-019-0984-2
  58. Hua, J.; Wang, X.; Ma, L.; Li, J.; Cao, G.; Zhang, S.; Lin, W. CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. Mol. Cancer, 2022, 21(1), 123. doi: 10.1186/s12943-022-01595-9
  59. Chung, E.K.; Yong, S.H.; Lee, E.H.; Kim, E.Y.; Chang, Y.S.; Lee, S.H. New targeted therapy for non-small cell lung cancer. Tuberc. Respir. Dis. (Seoul), 2023, 86(1), 1-13. doi: 10.4046/trd.2022.0066
  60. Shah, R.; Lester, J.F. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: A clash of the generations. Clin. Lung Cancer, 2020, 21(3), e216-e228. doi: 10.1016/j.cllc.2019.12.003
  61. Li, Y.; Shen, Y.; Xie, M.; Wang, B.; Wang, T.; Zeng, J.; Hua, H.; Yu, J.; Yang, M. LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1. Signal Transduct. Target. Ther., 2022, 7(1), 30. doi: 10.1038/s41392-021-00847-2
  62. Xu, L.M.; Yuan, Y.J.; Yu, H.; Wang, S.; Wang, P. LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis. J. Transl. Med., 2022, 20(1), 350. doi: 10.1186/s12967-022-03516-2
  63. Chen, Z.; Chen, Z.; Xu, S.; Zhang, Q. LncRNA SOX2-OT/miR-30d-5p/PDK1 regulates PD-L1 checkpoint through the mtor signaling pathway to promote non-small cell lung cancer progression and immune escape. Front. Genet., 2021, 12, 674856. doi: 10.3389/fgene.2021.674856
  64. Xia, R.; Geng, G.; Yu, X.; Xu, Z.; Guo, J.; Liu, H.; Li, N.; Li, Z.; Li, Y.; Dai, X.; Luo, Q.; Jiang, J.; Mi, Y. LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs. J. Immunother. Cancer, 2021, 9(8), e002746. doi: 10.1136/jitc-2021-002746
  65. Du, Z.; Niu, S.; Wang, J.; Wu, J.; Li, S.; Yi, X. SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis. Autoimmunity, 2021, 54(4), 225-233. doi: 10.1080/08916934.2021.1913582
  66. Li, J.; Che, L.; Xu, C.; Lu, D.; Xu, Y.; Liu, M.; Chai, W. XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8+ T cells. J. Recept. Signal Transduct. Res., 2022, 42(5), 469-478. doi: 10.1080/10799893.2021.2019274

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bentham Science Publishers